WuXi Advanced Therapies
WuXi Advanced Therapies is a global Contract Testing Development and Manufacturing Organisation (CTDMO) headquartered in Philadelphia, USA,
in the heart of the cell and gene therapy industry. It is the advanced therapies business unit of WuXi AppTec and provides innovative technology platforms for lentiviral and AAV plasmid, viral vector and cell therapy manufacture and testing, accelerating time to market for cell and gene therapies.
We are a comprehensive provider of viral vector and cell therapy testing for the advanced therapy industry, conducting testing for both therapeutics developers
and other CDMOs. With OXGENE as our UK-based discovery engine, our in-house testing capabilities and significant manufacturing expertise combine to provide a fully integrated end-to-end solution for cell and gene therapy research, development, testing and GMP manufacture that delivers a critical competitive advantage to our customers as we work together to cure faster and cure more.